Loading stock data…
VSTM
$5.84+0.38 (+6.96%)
Market ClosedLast close May 1
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Verastem, Inc. in the Healthcare sector is trading at $5.84. The stock is currently 48% below its 52-week high of $11.25, remaining 22.0% below its 200-day moving average. Technical signals show neutral RSI of 53 and bearish MACD signal, explaining why VSTM maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 53) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$5.84
Potential Upside
5%
Whystock Fair Value$6.13
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus8 analysts
Mean target$16.38+180.4%
Range$14.00 – $19.00
Fundamentals
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$547.26M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.43
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-128.48%
Volume
Today's trading volume
2.02M
Recent News
Cancer Stocks to Buy as Innovation Reshapes Global Oncology Market
Oncology is evolving fast as immunotherapy, AI and targeted drugs expand treatment options, boost outcomes, and fuel long-term healthcare growth.
Wall Street Analysts See a 159.31% Upside in Verastem (VSTM): Can the Stock Really Move This High?
The mean of analysts' price targets for Verastem (VSTM) points to a 159.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Verastem (VSTM) Q4 2025 Earnings Call Transcript
Daniel Paterson: Thank you, Julissa. 2025 was a truly transformative year for Verastem as we transition to a commercial stage company following our FDA approval of the first treatment specifically for KRAS-mutated recurrent low-grade serous ovarian cancer, nearly two months ahead of our PDUFA date. Before I continue, I want to address the updated NCCN ovarian cancer guidelines that were released last week and mentioned in our press release today.
Verastem, Inc. Q4 2025 Earnings Call Summary
Moby summary of Verastem, Inc.'s Q4 2025 earnings call
Verastem Inc (VSTM) Q4 2025 Earnings Call Highlights: Transition to Commercial Stage and ...
Verastem Inc (VSTM) reports significant revenue growth and FDA approval, but faces hurdles with NCCN guidelines and financial losses.